| COVID-19 |
1 |
1 |
| Thromboembolism |
0 |
0.97 |
| Aspirin |
0 |
0.62 |
| COVID-19 Treatment |
0 |
0.98 |
| Antithrombotics |
0 |
0.99 |
| Hospital |
0 |
0.41 |
| Heart |
0 |
0.28 |
| Cerebrovascular Accident |
0 |
0.23 |
| Pandemic |
0 |
0.95 |
| Cardiovascular Risk Management |
0 |
0.96 |
| Face |
0 |
0.14 |
| Infarction |
0 |
0.14 |
| Myocardial Infarction (MI) |
0 |
0.1 |
| Ambulatory Care |
0 |
0.07 |
| Anticoagulation Therapy |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| COVID-19 Testing |
0 |
0.07 |
| Hand |
0 |
0.07 |
| Inpatient Care |
0 |
0.07 |
| Lung |
0 |
0.07 |
| Severe Acute Respiratory Syndrome |
0 |
0.07 |
| Thrombosis |
0 |
0.07 |
| Acute Respiratory Distress Syndrome |
0 |
0.05 |
| Mechanical Ventilation |
0 |
0.05 |